Previous close | 24.17 |
Open | 24.30 |
Bid | 24.81 x 300 |
Ask | 25.00 x 100 |
Day's range | 24.30 - 24.98 |
52-week range | 23.29 - 35.56 |
Volume | |
Avg. volume | 500,161 |
Market cap | 1.172B |
Beta (5Y monthly) | 1.14 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals Inc (NASDAQ:MIRM), executed a sale of 4,303 shares in the company on March 25, 2024, according to a recent SEC Filing.
Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.